A Dose Escalation Tolerance and Pharmacokinetics Study of AL8326 in Advanced Solid Tumor
Latest Information Update: 06 Dec 2023
At a glance
- Drugs AL-8326 (Primary)
- Indications Advanced breast cancer; Cervical cancer; Colon cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Advenchen Laboratories
- 20 May 2021 New trial record